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Glycosyltransferase activitiesHeparan sulfates are complex sulfated molecules found in abundance at cell surfaces and in the extracellular
matrix. They bind to and inﬂuence the activity of a variety of molecules like growth factors, proteases and
morphogens and are thus involved in various cell–cell and cell–matrix interactions. Themammalian EXT proteins
have glycosyltransferase activities relevant for HS chain polymerization, however their exact role in this process
is still confusing. In this review, we summarize current knowledge about the biochemical activities and some
proposed functions of the members of the EXT protein family and their roles in human disease.
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Heparan sulfate (HS) proteoglycans (PGs) are ubiquitous compo-
nents of the extracellular matrix and play important roles in tissue, University of Bergen, Jonas Lies
sche-Gullberg).
ted equally to this work.
vier Inc.Open access under CC BY-NChomeostasis (Kim et al., 2011). They are essential for signal transduction
of many signaling molecules driving processes such as cell survival,
division, migration, differentiation and cancer development (reviewed
in (Li, 2008)). HSPGs are synthesized in a multistep process that is
initiated by the formation of a tetrasaccharide linkage region attached
to a selected serine residue in the core protein (GlcAβ1-3Galβ1-
3Galβ1-4Xylβ1-O-Ser (where GlcA, Gal and Xyl are glucuronic acid,
galactose and xylose, respectively). After the addition of an α1,4-linked
N-acetylglucosamine (α1,4-GlcNAc) residue, elongation proceeds by
the action of glycosyltransferases which add β1,4-linked GlcA and
α1,4-linked GlcNAc units in alternating sequence to the nonreducing
end of the growing polymer (Fig. 1). Concomitantwith chain elongation
several modiﬁcations occur through an epimerase and various sulfo-
transferases that generate a complex polysaccharide containing N-
acetylated and N-sulfated glucosamine residues, GlcA and iduronic acid
(IdoA) units, as well as O-sulfate groups in various positions (Lindahl-ND license.
Fig. 1. Schematic illustration of the different glycosyltransferase activities involved in HS chain elongation. HS biosynthesis is initiated by the assembly of a polysaccharide-protein linkage
tetrasaccharide (GlcAβ1-3Galβ1-3Galβ1-4Xyl) to a particular serine residue in the core protein. After addition of a single α1,4-linked GlcNAc (GlcNAc-transferase (-T) I activity), the
(GlcA-GlcNAc)n HS precursor chain is formed by the alternating addition of β1,4-linked GlcA and α1,4-linked GlcNAc residues by glycosyltransferase/s with GlcATII and/or GlcNAcTII
activities. If an α1,4-linked GalNAc is added to the tetrasaccharide linkage by αGalNAc-transferase this terminates further chain elongation. It should be noted that αGalNAc-
transferase activity has only been detected in in vitro studies and that the product has never been identiﬁed in native proteoglycans.
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et al., 2007; Kreuger and Kjellen, 2012). The synthesis of HS backbone
is mediated by glycosyltransferases of the exostosin family (EXTs). Five
genes encoding EXT proteins have been identiﬁed in mammals, EXT1,
EXT2, EXTL1, EXTL2, and EXTL3 (Table 1).
EXT1 and EXT2 were ﬁrst recognized as two out of three genes that
were responsible for the autosomal inherited disorder hereditary mul-
tiple osteochondromas (HMO, also called hereditarymultiple exostoses,
HME), by genetic linkage analysis in 1993–1994 (Cook et al., 1993;
LeMerrer et al., 1994; Wu et al., 1994). The three disease genes, located
at three distinct chromosomes 8, 11 and 19, were called exostosins and
named EXT1, EXT2 and EXT3, respectively. The EXT1 and EXT2 genes
were shortly afterwards cloned and characterized (Ahn et al., 1995;
Stickens et al., 1996) whereas EXT3 has so far not been identiﬁed and
its linkage to HMO has been questioned. The protein sequence of EXT1
and EXT2 showed structural similarities but their functions remained
unknown until two independent studies linked EXT1 and EXT2 to HS
synthesis (Lind et al., 1998; McCormick et al., 1998).
The other members of the EXT-family, the EXT-like proteins, EXTL1,
EXTL2 and EXTL3, have not been linked to HMO. Instead they were
identiﬁed in screens for proteins homologous to EXT1 and EXT2 (Wise
et al., 1997; Wuyts et al., 1997; Van Hul et al., 1998). EXTL2 and EXTL3
are also referred to as products of EXT-related genes 2 and 1 (EXTR2
and EXTR1), respectively. Since the three EXTL-proteins share amino
acid sequence homology with EXT1 and EXT2, it is expected that these
proteins also might be involved in HS synthesis.
The EXT proteins are well conserved, especially in their C-terminal
parts (Fig. 2). Several conserved cysteine residues are found in all
EXTs, suggesting that they share a common structural fold. Except for
EXTL1 they all contain one or more conserved aspartic acid-any amino
acid-aspartic acid (DXD) motifs (Zak et al., 2002) typical for glyco-
syltransferases utilizing nucleotide-activated sugars as donor substrates
(Breton et al., 1998). EXTL2 is the shortest member of the EXT family
consisting of ~330 amino acids whereas EXTL3 is signiﬁcantly larger
than the other members of the EXT family (~900 aa, Table 1) (VanTable 1
Human and mouse exostosin genes.
Gene Human
Chromosome number mRNA accession Amino acid
EXT1 8 NM_000127 746
EXT2 11 NM_000401 718
EXTL1 1 NM_004455 676
EXTL2 1 NM_001033025 330
EXTL3 8 NM_001440 919Hul et al., 1998) and contains an N-terminal fragment with no homol-
ogy with the other family members.
Except for EXTL1, the EXT familymembers are ubiquitously expressed
in mammalian tissues. EXTL1 mRNA expression in adult human and
mouse seems to be limited to a few tissues. Northern blot analyses
show high expression of human EXTL1 in skeletal muscles and brain
and lower transcript levels in heart (Wise et al., 1997). Gene proﬁling
shows, that in addition to being highly expressed in skeletal muscle
and brain, the human EXTL1 is expressed in skin (TiGER database:
http://bioinfo.wilmer.jhu.edu/tiger/). In the mouse embryo the highest
expression is found in the skeleton, limb and nose (Eurexpress:
http://www.eurexpress.org/ee/intro.html). Northern blot analyses of
the adult mouse EXTL1 mRNA transcript showed, with one exception,
transcript patterns similar to those of the human EXTL1 mRNA with
expression in heart, skeletal muscle and the brain (Stickens et al.,
2000). In contrast to analyses of the human Northern blot, EXTL1 is
highly expressed in the adult mouse liver tissues (Stickens et al.,
2000), whereas the TiGER database shows low levels of the human
EXTL1 in liver. Future studies will determine if the different expression
levels have functional importance.
Little is known about the frequency of structural variants of the EXTs.
According to e!Ensemble (http://www.ensembl.org/index.html), all
human EXT-family members, except for EXTL1, can express several
putative splice forms resulting in protein products of different sizes.
Corresponding data for mouse list protein coding splice variants for Ext1,
Ext2 and Extl2. However, it is important to note that for the majority of
the listed splice variants no experimental conﬁrmation is available.
Therefore, their tissuedistributions and functional impacts are not known.
2. Proposed functions of the mammalian EXT family of proteins
2.1. EXT1 and EXT2
It has for many years been suggested that the GlcA- and GlcNAc
transferase activities required for HS chain elongation are located in aMouse
Chromosome number mRNA accession Amino acid
15 NM_010162 746
2 NM_010163 718
4 NM_019578 669
3 NM_001163514 330
14 NM_018788 919
Fig. 2.Amino acid sequence comparison of human EXT/EXTL proteins. Conserved and similar residues are highlightedwith black and gray boxes, respectively. Conserved cysteins are labeled in red andDXDmotifs in blue. The sequenceswere aligned
using the Clustal W software and the alignments were manually corrected.
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28 M. Busse-Wicher et al. / Matrix Biology 35 (2014) 25–33single protein (Lidholt et al., 1992). In 1993 a protein that catalyzed the
in vitro transfer of both GlcA and GlcNAc to the appropriate substrates
was puriﬁed from bovine serum (Lind et al., 1993). Cloning of the
corresponding cDNA identiﬁed the putative GlcA/GlcNAc transferase
as EXT2 (Lind et al., 1998). At the same time an independent study
demonstrated EXT1 to restore HS biosynthesis in an HS-deﬁcient cell
line (McCormick et al., 1998).
Early studies that looked at the glycosyltransferase activities of EXT1
and EXT2 tentatively implied that both EXT1 and EXT2 are bifunctional
enzymes that harbor GlcA- as well as GlcNAc-transferase (GlcA-TII and
GlcA-TII) activities (Fig. 1) involved in HS elongation (Lind et al., 1998;
McCormick et al., 2000; Senay et al., 2000). Analyses of mutant Chinese
hamster ovary (CHO) cells deﬁcient in HS, mapped the GlcA-transferase
domain to the N-terminal half of the EXT1 protein (Wei et al., 2000). So
far, the location of the GlcNAc-transferase domain remains unidentiﬁed.
Even though EXT1 alone is able to polymerize the HS backbone struc-
ture in vitro (Busse and Kusche-Gullberg, 2003; Kim et al., 2003) it has
been clearly recognized that both EXT1 and EXT2 are needed in vivo
for HS chain elongation. Lack of either EXT1 or EXT2 disrupts HS synthe-
sis indicating that both proteins are required for proper polymeriza-
tion (McCormick et al., 1998; Lin et al., 2000; Stickens et al., 2005).
Furthermore, neither of the two EXT proteins can substitute for the
other one. Thus, transfection of EXT2 into cells deﬁcient in EXT1 does
not restore HS synthesis (McCormick et al., 2000; Wei et al., 2000).
Since co-expression experiments showed that EXT1 and EXT2 form
hetero-oligomers and that the EXT1/EXT2 complex possessed substan-
tially higher glycosyltransferase and polymerizing activities than ei-
ther EXT1 or EXT2 alone it was further suggested that the biologically
functional unit in HS polymerization is a co-polymerase in which both
EXT1 and EXT2 are essential for activity (McCormick et al., 2000;
Senay et al., 2000; Busse and Kusche-Gullberg, 2003; Busse et al.,
2007). Interestingly, the interaction and catalytic activities observed
after co-expression of EXT1 and EXT2 were not observed bymixing cel-
lular lysates of separately EXT1- and EXT2-expressing cells or separately
expressed recombinant EXT1 and EXT2 indicating that EXT1 and EXT2
proteins need to be simultaneously synthesized in the cell in order to
attain full catalytic efﬁcacy (Senay et al., 2000).
The EXT1protein has readily detectable GlcA- andGlcNAc-transferase
activities whereas it has been difﬁcult to pinpoint the catalytic activities
of EXT2. No increase in glycosyltransferase activities could thus be
detected after overexpression of EXT2 inmammalian cells. The problem
is further complicated by the tendency of EXT1 and EXT2 to associate
with each other and to remain associated also after puriﬁcation of
recombinant proteins (Kobayashi et al., 2000; McCormick et al., 2000;
Senay et al., 2000). Therefore, the early studies of the glycosyltrans-
ferase activities of EXT2 have been questioned. Instead, the function of
EXT2 has been suggested to be assisting in the transport (and maybe
also the folding) of EXT1 and the ﬁrst HS modifying enzyme, a com-
bined N-deacetylase/N-sulfotransferase, from the ER to the Golgi com-
plex (Busse et al., 2007; Presto et al., 2008). Moreover, in vitro, a
complex of recombinant EXT1 and EXT2 has been shown to polymerize
HS directly onto a protein-linkage region lacking the ﬁrst GlcNAc,
implicating additional GlcNAc-TI activity for the EXT1/2 complex (Kim
et al., 2003). At present, no in vivo data are yet available to conﬁrm
the lack of the ﬁrst GlcNAc residue in the protein-linkage region of
Ext1 or Ext2 deﬁcient cells. Also, CHO cells deﬁcient in Ext1 produce
a recombinant proteoglycan with a tetrasaccharide linkage region
containing one additional GlcNAc residue (Zhang and Esko, 1995),
suggesting that also other proteins can add this residue to the linkage
region. In fact, another member of the EXT-family, EXTL3, has been
shown to perform this activity in vitro and mice deﬁcient in Extl3 are
not able to produce HS (Takahashi et al., 2009), implying a more
complex regulation of HS biosynthetic machinery in vivo. In addition
to their involvement in HS synthesis, EXT1 and EXT2 were found to
bind to the heat shock protein tumor necrosis factor type I associated
protein (TRAP-1) and EXT2 was further shown to strongly interactwith polypeptide GalNAc transferase T5 (Simmons et al., 1999). These
studies raise the possibility that the function of EXT2 is not only to act
as partner in HS biosynthesis but it may also have more complex
functions such as being an interacting and/or cellular transporting
partner for different molecules.
2.2. EXTL1
EXTL1 has been identiﬁed as a GlcNAc transferase catalyzing the
addition of a GlcNAc to substrates mimicking the non-reducing end
of growing HS chain (GlcNAc-TI activity, Fig. 1) (Kim et al., 2001).
There are very few reports regarding the biochemistry of EXTL1, most
probably due to its limited expression level. Yet, there are several
reports on changes in EXTL1mRNA expression levels at different stages
of cellular development and in tumors (Liu et al., 2006; Gu et al., 2008).
For example, EXTL1 expression is down-regulated in chorionic villi
samples of 10–11 old euploid fetuses with increased nuchal trans-
lucency (ﬂuid collection behind the neck of the fetus) (Farina et al.,
2006). Extl1 mRNA levels, but not those of the other Exts, are up-
regulated during differentiation of C2C12 myoblast into myotubes,
indicating that Extl1 may be involved in myogenic differentiation
(Janot et al., 2009). Transgenic mice overexpressing Extl1 in a B-cell
speciﬁc manner show a blockage of early B-cell maturation (Duchez
et al., 2011). The effect could be attributed to the overexpression of
Extl1 in the B-cell linage, since heparin addition to cells in vitro had no
effect. Notably, in the above mentioned studies, no attempts were
made to analyze HS structure so the link of Extl1 expression levels to
HS synthesis remains to be determined. Furthermore, since expression
of HS synthesizing enzymes may be translationally controlled (Grobe
and Esko, 2002), information about protein instead of transcript levels
will be important. So far, no mutants of EXTL1 have been described so
the precise role of EXTL1 in vivo remains elusive. Its restricted expres-
sion suggests a more specialized function than expected of a glycosyl-
transferase involved in HS synthesis.
2.3. EXTL2
EXTL2 has been demonstrated to have two in vitro glycosyltrans-
ferase activities, transfer of either α-linked GlcNAc or α-linked N-
acetylgalactosamine (GalNAc) to the tetrasaccharide linkage region
(Kitagawa et al., 1999; Okada et al., 2010). The functional signiﬁcance
of theα-linkedGalNAc transfer is difﬁcult to understand since the prod-
uct is not an acceptor for glycosyltransferases involved in glycos-
aminoglycan synthesis (Fig. 1) and has never been identiﬁed in native
proteoglycans. Both HS and chondroitin sulfate (CS) polymerization
are initiated on the tetrasaccharide linkage region. The addition of the
ﬁrst GlcNAc residue to the linkage tetrasaccharide region is the key
step to the initiation of HS polymerization and is carried out by a unique
glycosyltransferse, GlcNAc-TI, which differs from the corresponding
enzyme/s involved in chain elongation. Although EXTL2 exhibits
in vitro transferase activity that could correspond to an initiator of HS
synthesis (GlcNAc-TI activity, Fig. 1) this activity is weak and has been
detected only with a synthetic linkage-region analog as substrate but
not with the authentic linkage tetrasacccharide substrate (Kitagawa
et al., 1999). In fact, recombinant EXTL2 was found to transfer α-linked
GalNAc much more efﬁciently than α-linked GlcNAc to the synthetic
linkage-region analog (Kitagawa et al., 1999; Pedersen et al., 2003) that
may suggest a function for this enzyme other than as an initiator of HS
biosynthesis. The enzyme could possibly catalyze the formation of a
novel glycan, perhaps unrelated to proteoglycan assembly. However, in
an Ext1 deﬁcient mouse ﬁbroblast cell line, gro2C (McCormick et al.,
1998), EXTL2 has been proposed to initiate HS synthesis by transferring
GlcNAc to the linkage region followed by EXT2-mediated elongation of
HS chains (Okada et al., 2010). The EXT2 polymerized chains are
considerably shorter than HS chains from wild-type ﬁbroblast cells.
Intriguingly, a similar shortening of HS chains is observed in embryonic
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about 3% of wild type Ext1mRNA (Yamada et al., 2004).
In a recent article another function for EXTL2 as a suppressor of
glycosaminoglycan (HS and CS) synthesis in the mouse liver was
proposed (Nadanaka et al., 2013b). The authors show that EXTL2-
mediated transfer of GlcNAc to a linkage region containing a phosphory-
lated Xyl residue prevents further chain elongation (Nadanaka et al.,
2013b). Additionally, mouse liver cells lacking EXTL2 produce signiﬁ-
cantly more HS and CS during liver repair (Nadanaka et al., 2013a).
The increase in sulfated glycosaminoglycan synthesis had no detectable
impact on normal animal physiology but impaired the regeneration
process of the liver (Nadanaka et al., 2013a). The ﬁndings regarding
the role of EXTL2 as a terminator of HS chain elongation (when the
linkage region contains a phosphorylated xylose) and the results sug-
gesting that, in the absence of EXT1, EXTL2 initiates HS synthesis are
puzzling and may indicate a cell speciﬁc regulation of HS synthesis.
Clearly, additional more reﬁned experiments will be needed to resolve
the function of EXTL2 and its role in glycosaminoglycan synthesis.
2.4. EXTL3
EXTL3 has been ascribed two glycosyltransferase activities, GlcNAc-
TI and GlcNAc-TII (Fig. 1), and thus may be involved in the initiation
and elongation of HS chains (Kim et al., 2001). siRNA mediated gene
silencing experiments in mammalian cells demonstrated that reduced
EXTL3 levels results in synthesis of longer HS chains whereas overex-
pression of EXTL3 had no obvious effect on HS chain length (Busse
et al., 2007). These results indicated that lowering the amount of
EXTL3 results in fewer linkage regions containing the GlcNAc necessary
for the start of HS elongation. With less acceptor substrates available,
more extensive polymerization of the chains that are being synthesized
can occur. Furthermore, no HS was detected in 9-day old mouse
embryos lacking EXTL3 (Takahashi et al., 2009) and mutations in
corresponding enzymes in Drosophila melanogaster (Bornemann et al.,
2004; Takei et al., 2004), Caenorhabditis elegans (Morio et al., 2003)
and Danio rerio (Lee et al., 2004) led to reduced HS synthesis. Taken
together, these data suggest that EXTL3 is an initiator of HS chains.
In addition to being a glycosyltransferase, the N-terminal part of
the EXTL3 protein has been associated with TNF-α-induced nuclear
factor-κB (NF-κB) activity (Mizuno et al., 2001). EXTL3 has also been
proposed to be a cell surface receptor for regenerating islet-derived
proteins (REGs). The REG family is a group of secreted proteins with a
C-type lectin-like domain involved in proliferation and differentia-
tion of several different cell types (Parikh et al., 2012). In 2000, EXTL3
was ﬁrst described as a cell surface receptor for a rat pancreatic REG-
protein (Kobayashi et al., 2000). Following this publication several
other publications have claimed EXTL3 to be a cell surface receptor
for different members of the REG-family (Levetan et al., 2008; Mueller
et al., 2008; Acquatella-Tran Van Ba et al., 2012; Lai et al., 2012).
However, it is unclear if EXTL3 binds directly to REG proteins or not.
Lai et al. (2012) found that binding of recombinant REG3A to kera-
tinocyte EXTL3 promoteswound re-epithelialization through activation
of the phosphatidylinositol 3 kinase (PI3K)-AKT signaling pathway (Lai
et al., 2012). Binding of REG1 to rat pancreatic-derived cells, supposedly
via EXTL3, induces growth by activating a MAPK-cyclin D1 pathway
(Mueller et al., 2008). Immunoprecipitation studies of REG3A treated
keratinocytes showed association of EXTL3 with REG3A (Lai et al.,
2012) whereas in a yeast two-hybrid system no physical association
of rat Reg-1 protein with EXTL3 was observed (Mueller et al., 2008).
Furthermore, EXTL3 silencing in keratinocytes had no effect on the
HS-dependent ﬁbroblast growth factor 7- (FGF7) mediated in vitro
wound induced re-epithelialization but decreased REG3A induced re-
epithelialization (Lai et al., 2012). This result, together with the fact
that syndecan-1 expression was unchanged after EXTL3 silencing, was
interpreted to suggest that the effect of EXTL3 on REG3A mediated
keratinocyte proliferation was independent of HS or HS binding growthfactors. However, no attempts were made to quantify HS. At this stage,
one cannot rule out that EXTL3 is a receptor for REG-proteins, however,
how and if this property relates to HS synthesis is not known. Clearly,
further studies of EXTL3 is needed to understand the proposedmultiple
roles of EXTL3.
3. EXT orthologs and animal mutants
Phylogenetic analyses of EXT family based on amino acid sequence
alignments show that EXT1, EXT2 and EXTL3 most likely have already
been present in the last common ancestor of all eumetazoans (Feta
et al., 2009)(Fig. 3). In contrast, EXTL1 and EXTL2 genes are present
only in vertebrates, probably appearing with the emergence of ﬁsh.
EXTL1 is more closely related to EXT1 than the other EXT family
members and the EXTL1 gene seems to result from a duplication of the
whole EXT1 gene before the appearance of jawless ﬁsh (lampreys,
hagﬁsh). EXTL2 is the most divergent and may have arisen via partial
duplication of the EXTL3 gene in the ancestors of the jawed ﬁsh.
The importance of EXT1, EXT2, and EXTL3 for HS synthesis and HS-
dependent signaling has been shown in several animal models. Loss of
function of these genes inmouse,D. rerio,D. melanogaster and C. elegans
causes developmental abnormalities (Table 2) most probably due to
defective morphogen/growth factor signaling. Below is a short presen-
tation of model organisms with loss of functions caused by mutations
in the genes encoding EXT-family members.
Ext1 and Ext2-deﬁcient mouse embryos exhibit the same devel-
opmental abnormalities; they lack HS, fail to gastrulate and die around
embryonic day 8.5 (Lin et al., 2000; Stickens et al., 2005). In contrast,
mice carrying a hypomorphic mutation in Ext1 generated by gene
trapping (Ext1Gt/Gt) (Mitchell et al., 2001) survive to embryonic day
14.5 (Koziel et al., 2004). The longer survival time of the Ext1Gt/Gt mice
may be explained by the fact that they still produce small amounts of
Ext1, which results in synthesis of short but apparently normally
sulfated HS chains (Yamada et al., 2004). Conditional disruption of
Ext1 in the developing mouse brain results in severe brain defects
(Inatani et al., 2003; Yamaguchi et al., 2010). Extl3 deﬁcient mice die
around E9 and cell speciﬁc ablation of Extl3 in mouse pancreatic islets
affects the maturation of postnatal islets due to a reduced HS synthesis
(Takahashi et al., 2009).
Zebraﬁsh have three EXT1 genes (ext1a, ext1b and ext1c) with
different expression patterns that may suggest functional divergence
(Siekmann and Brand, 2005). Mutations in the zebraﬁsh orthologs of
EXT2 (ext2/dackel) and EXTL3 (extl3/boxer) result inmissorting of retinal
ganglion cells and drastically reduced HS levels (Lee et al., 2004).
Interestingly, the reduction of HS synthesis in the extl3 mutants are
accompanied by increased CS synthesis indicating that linkage regions
that are not initiated by extl3 and thus do not form HS, instead are
used as primers for CS synthesis (Holmborn et al., 2012).
The Drosophila orthologs of the mammalian EXT genes, tout velu
(ttv), sister of ttv (sotv or dEXT2) and brother of ttv (botv or dEXTL3),
correspond to mammalian EXT1, EXT2 and EXTL3, respectively (Fig. 3).
The Drosophila EXT/L genes were identiﬁed in genetic screens for
mutations affecting morphogen signaling and mutations in any of
these genes lead to reduction or abolishing of HS synthesis (The et al.,
1999; Tsuda et al., 1999; Toyoda et al., 2000; Bornemann et al., 2004;
Takei et al., 2004). Interestingly, due to translational control of HS
biosynthetic enzymes, including ttv, HS synthesis in Drosophila is
temporally regulated (Bornemann et al., 2008), indicating that
translational regulation may represent an important control of HS
synthesis.
C. elegans genome has only two EXT familymembers, rib-1 and rib-2.
Based on amino acid sequence homology, RIB-1 and RIB-2 appear
to correspond to mammalian EXT1 and EXTL3, respectively (Fig. 3B).
Complete loss of functionmutations of rib-1 or rib-2 result in embryonic
lethality and reduced HS synthesis (Morio et al., 2003; Kitagawa et al.,
2007).
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embryos leads to abnormal dorsal–ventral axis formation (Tao et al.,
2005).
3.1. Enzyme activities of non-mammalian EXT-proteins
So far biochemical enzyme activity studies of non-mammalian
species have been performed on recombinantly expressed Drosophila
and C. elegans EXT-proteins.
In vitro enzyme assays of soluble recombinant forms of theDrosophila
enzymes expressed in COS-1 cells revealed similar enzyme activities to
those of their mammalian counterparts. BOTV has both GlcNAc-TI and
-TII activities involved in initiation and polymerization (Kim et al.,
2002). TTV and SOTV have GlcA- and GalNAc-TII activities in vitro and
enhanced activities upon co-expression suggesting that, similar to their
mammalian counterparts, both proteins participate in HS polymerization
(Izumikawa et al., 2006).
The lack of an EXT2 homolog indicates that in C. elegans the activities
of RIB-1 and RIB-2 are sufﬁcient for the production of HS chains. Soluble
RIB-2 has similar in vitro glycosyltransferase activities as the other
EXTL3proteins, it catalyzes the transfer of GlcNAc in vitro onto acceptors
mimicking HS chain initiation and elongation (Kitagawa et al., 2001).
RIB-1 exhibits no transferase activities meaning that neither of the
worm transferases shows any GlcA-transferase activity as single pro-
teins. Still, when co-expressed, the RIB-1/RIB-2 complex exhibits both
GlcA- and GlcNAc-T activities and is able to polymerize HS chains on
a linkage region (Kitagawa et al., 2007). RIB-1 lacks a signal sequence,
a transmembrane domain and has only one of the conserved DXD-
motifs. RIB-1 is about half as long as RIB-2 and the human EXT1, the
protein corresponds to the N-terminal part of EXT1, which potentially
comprises the GlcA-T domain (Wei et al., 2000; Zak et al., 2002). rib-1
and rib-2 mutants both exhibit reduced amounts of HS demonstrating
in vivo evidence for their requirement for HS synthesis in C. elegans
(Morio et al., 2003; Kitagawa et al., 2007) (Table 2).
4. Pathologies associated with the human EXT family of proteins
Mutations in either EXT1 or EXT2 cause hereditary multiple osteo-
chondromas (HMO), an autosomal dominant disorder characterized
by bone deformities and cartilage-capped bony outgrowths, called
exostoses or osteochondromas, at the ends of the long bones (reviewed
in (Jennes et al., 2009)). HMO is one of the most common inherited
skeletal disorders with an estimated incidence of 1–2 per 100 000 live
births. The most serious complication is malignant degeneration to
chondro- or osteosarcomas, which occurs in 2–5% of the patients. The
patients are heterozygous for the mutation and a number of mutations
in EXT1 and EXT2 have been reported in HMO patients (Jennes et al.,
2009). The mutations are randomly distributed over the entire EXT1
gene, whereas EXT2 mutations appear to be concentrated towards
the N-terminal part of the protein. Most mutations result in premature
termination of translation and loss of function. Less common are
missense mutations affecting single amino acids resulting in loss of
EXT activity (Jennes et al., 2009). Many theories on the mechanism by
which osteochondroma develop have been proposed and contradictory
reports are present on the cellular origin of the osteochondroma.
Proposed candidates at the growth-plate include chondrocytes, peri-
chondrial cells and cells of the groove of Ranvier. Although tumor
suppressor properties were ascribed early to EXT1 and EXT2, it remains
unclear if EXT1 and EXT2 ﬁt the classic two-hit model for tumor
suppressor genes, which implies that osteochondroma results from
a somatic mutation in the remaining wild-type copy of the gene
(Knudson, 1971). Another possibility is that osteochondromas may
arise from haploinsufﬁency in the EXT1 or EXT2 genes, resulting in
reduced HS synthesis. For these aspects of HMO and the description of
several animal models that have been developed to understand the
pathogenesis and the underlying molecular events of HMO the readersare referred to (Bovee, 2010; Roehl and Paciﬁci, 2010; Sarrazin et al.,
2011; de Andrea and Hogendoorn, 2012; Huegel et al., 2013) and
references therein. In addition to skeletal dysfunction, HMO patients
complain about other problems, such as childhood autism-like symp-
toms, digestive problems, muscle weakness, and atherosclerosis (Roehl
and Paciﬁci, 2010) which all may be caused by a reduced HS content. In
fact, autism has been suggested to be associated with HMO (Li et al.,
Fig. 3.A) Phylogenetic tree of EXT/L orthologs fromvariousmetazoan species: The treewas generatedusing themaximumparsimony algorithm implemented by theMega 5 software. The
turkey (MgaEXT1c), lizard (AcaExt1c), turtle (CmyExt1b) and zebraﬁsh (DreExt1c) groupwith the EXTL1. Theymay represent Extl1 genes. However, we can currently not exclude that these
genes and the jawless ﬁsh latimeria (LchExt1c/d) and lamprey (PmeExtl1) represent Ext1 genes. Nve — Nematostella vectensis (anemone), Dme — Drosophila melanogaster (ﬂy), Cel —
Caenorhabditis elegans (nematode), Spu — Strongylocentrotus purpuratus (urchin), Cin — Ciona intestinalis (tunicate), Bfa — Branchiostoma ﬂoridae (lancelet), Pma — Petromyzon marinus
(lamprey), Dre — Danio rerio (ﬁsh), Lch — Latimeria chalumnae (coelacanth), Aca — Anolis carolinensis (lizard), Gga — Gallus gallus (chicken), Mga — Meleagris gallopavo (turkey),
Oan — Ornithorhynchus anatinus (platypus), Mmu — Mus musculus (mouse), and Hsa — Homo sapiens (human). B) Comparison of amino acid sequence identities between EXT-family
members in different species. The numbers show the percent of the identical amino acids in pair-wise aligned sequences using the ClustalW software. Notice the relatively low overall
degree of sequence conservation between the human EXT-protein family members.
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exhibit autism-like behavioral phenotypes (Irie et al., 2012). Multiple
osteochondromas are also observed in patients with two contiguous
gene syndromesmapped to chromosomes 8 (Langer–Giedion syndrome)
(Cook et al., 1993; Ludecke et al., 1995) and 11 (defect 11 syndrome)
(Wu et al., 1994; Wuyts et al., 1995) due to deletions or mutations in
EXT1 and EXT2, respectively, in addition to loss of neighboring genes.
In addition to a role in HMO, epigenetic inactivation of EXT1 by
promoter hypermethylation resulting in inhibition of HS synthesis is
found in leukemia and non-melanoma cancer cells and re-introduction
of EXT1 into cancer cells induced a tumor suppressing effect (Ropero
et al., 2004). In contrast, high expression of EXT1 in patients with
multiple myeloma was reported to be associated with a poor prognosis
(Bret et al., 2009). EXT2 ismutated in breast carcinomapatients (Yoneda
et al., 2012) and both EXT1 and EXT2 have altered N-glycosylation inTable 2
Animal models with loss of function mutations in EXT genes.
Model Gene Mutant phenotype
Mus musculus (mouse) Ext1−/− Embryonic lethality (~E 7.5). Fa
Ext1Gt/Gt Embryonic lethality around E 14
Ext2−/− Embryonic lethality (E 6–7.5). F
Extl1 No mutants reported
Extl2−/− Viable, normal life span, impaire
Extl3−/− Embryonic lethality (~E 7.5–9).
Extl3cond Conditional mutant — cell speci
postnatal islet maturation. Redu
Drosophila melanogaster
(fruit ﬂy)
tout-velu (ttv) (Ext1) Segment polarity phenotype, im
sister of tout-velu (sotv)
(Ext2)
Segment polarity phenotype, im
brother of tout-velu
(botv) (Extl3)
Segment polarity phenotype, im
Danio rerio (zebraﬁsh) dackel (dak) (Ext1) Partial mutant (due to maternal
in the optic tract, ﬁn defects. Re
Boxer (box) (Extl3) Partial mutant (due to maternal
in the optic tract, ﬁn defects. Re
Caenohabditis elegans
(nematode)
rib-1 (Ext1) Embryonic lethality. Impaired H
rib-2 (Extl3) Embryonic lethality. Impaired Hhuman aggressive breast cancer cell lines (Drake et al., 2012). However,
it is not known how or if these latter modiﬁcations affect the activity of
the EXT-proteins and thus HS structure. Additionally, in hepatocellular
carcinoma, frequent inactivation of one allele (loss of heterozygosity)
of EXT1 has been described (Piao et al., 1997).
The EXTL-genes are not linked to HMO and have so far not been
associated with any diseases although their chromosomal locations
may indicate some involvements in certain types of cancer. EXTL1
maps to chromosome 1p36, a region that often is deleted in neuroblas-
toma. Based on its localization, EXTL1has been implicated as a candidate
involved in the etiology of these tumors. However, detailed molecular
analysis of EXTL1 in neuroblastoma patients and cell lines could not
conﬁrm that EXTL1 is directly involved in the development of neuro-
blastoma (Mathysen et al., 2004). EXTL2 has been assigned to a chro-
mosome region (1p11–p12) that is frequently rearranged in sporadicReferences
ilure to gastrulate. No HS chains. Lin et al. (2000)
.5. Short HS chains. Koziel et al. (2004),
Yamada et al. (2004)
ailure to gastrulate. No HS chains. Stickens et al. (2005)
d liver regeneration, increased synthesis of GAGs. Nadanaka et al. (2013a,b)
No detectable HS chains. Takahashi et al. (2009)
ﬁc ablation of Extl3 in pancreatic islet. Impaired
ced HS levels.
Takahashi et al. (2009)
paired morphogen distribution. Reduced HS synthesis. Bellaiche et al. (1998),
Bornemann et al. (2004)
paired morphogen distribution. Reduced HS synthesis. Bornemann et al. (2004),
Han et al. (2004),
Takei et al. (2004)
paired morphogen distribution. Reduced HS synthesis. Han et al. (2004),
Takei et al. (2004)
contribution). Retinal ganglion cell axons missorting
duced HS levels.
Lee et al. (2004)
contribution). Retinal ganglion cell axons missorting
duced HS levels.
Lee et al. (2004)
S synthesis. Kitagawa et al. (2007)
S synthesis. Morio et al. (2003)
32 M. Busse-Wicher et al. / Matrix Biology 35 (2014) 25–33cancer (Wuyts et al., 1997) but so far, there are no reports of EXTL2
mutations involved in any human disorder. EXTL3 is located on chro-
mosome 8p21 a frequent target for chromosomal aberrations in breast
cancer, is mutated in 25% of early colorectal carcinoma cell lines (Arai
et al., 1999) and is epigenetically down-regulated in certain sub-
types of colorectal cancers (Karibe et al., 2008), suggesting that EXTL3
gene alterations may be involved in the pathology of different human
carcinomas.
5. Concluding remarks
The requirement of HS for the development of metazoans is undis-
putable, as seen in D. melanogaster, C. elegans, Mus musculus, D. rerio
and othermodel organisms (BulowandHobert, 2006). The EXT proteins
are conserved between species, and in vivo data strongly indicate
common roles of EXT orthologs in HS biosynthesis. Yet in vitro ex-
periments have produced conﬂicting data regarding the molecular
mechanism of their mode of action. Still little is known about the
mechanisms governing HS chain elongation and the interactions of
the participating enzymes or to what extent these proteins have other
functions. Clearly, more studies are needed, not only to unravel the
biology of these molecules but also to understand how mutations in
EXT1 and EXT2, but not in the other EXT gene-family members, result
in hereditary multiple osteochondromas.
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